Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients

Kim, G A; Rim, Tyler Hyungtaek; Lee, S C; Byeon, Suk Ho; Koh, Hyoung Jun; Kim, Sung S.; Lee, Christopher Seungkyu

doi:10.1038/eye.2015.58

Cited by 22 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering this pattern is frequently seen in resolved CSC, and is related to a small SRF height, decreased choriocapillary hemodynamic instability has been demonstrated as more stable OCTA imaging and absorption of SRF. This hypothesis is consistent with previous reports that intravitreal anti‐VEGF treatment or PDT reduce subfoveal choroidal thickness and stabilize choroidal blood flow …”

Section: Discussionsupporting

confidence: 93%

“…In our study, eyes with resolved CSC also showed a greater decrease in choroidal thickness than eyes with active CSC (−51.9 μm vs −14.7 μm, Table ). A trend for a thicker choroidal thickness at baseline in eyes with resolved CSC (431.4 ± 129.3 μm) than in eyes with active CSC (378.8 ± 97.1 μm) was observed, with marginal statistical significance ( P = 0.073), which is consistent with mentioned reports …”

Section: Discussionsupporting

confidence: 91%

“…A greater baseline choroidal thickness is related to better response to anti‐VEGF treatment, as well as to a lower recurrence rate . Good responders to anti‐VEGF treatment also showed a larger decrease in choroidal thickness . In our study, eyes with resolved CSC also showed a greater decrease in choroidal thickness than eyes with active CSC (−51.9 μm vs −14.7 μm, Table ).…”

Section: Discussionsupporting

confidence: 53%

See 2 more Smart Citations

Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy

Seo

Yoon

2019

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Importance Analysing choroidal flow in central serous chorioretinopathy (CSC) with novel device. Background To examine the abnormal morphology of choriocapillary flow with optical coherence tomography angiography (OCTA) according to the presence of subretinal fluid (SRF) in CSC. Design A hospital‐based retrospective study. Participants We analysed OCTA results of 68 eyes (68 patients) diagnosed as CSC with or without SRF (active and resolved CSC, respectively) at the Asan Medical Center. Methods We classified OCTA choriocapillary images into three pattern groups: mixed perfusion, hyper‐perfusion and normal perfusion. Data analysis included age, follow‐up duration, treatment modalities, number of treatments, subfoveal choroidal thickness and SRF height. Main Outcome Measures The relationship between CSC activity and choriocapillary pattern. Results Abnormal choroidal flow (mixed and hyper‐perfusion) was more frequently found in eyes with active CSC (100%) than resolved CSC (47.5%, P < 0.001). In active CSC eyes, mixed perfusion was predominant (71.4%), while hyper‐perfusion was predominant in those with resolved CSC (73.7%). Eyes with recently resolved CSC (SRF absorption present for <2 months) had abnormal choriocapillary flow more often than the remaining eyes with resolved CSC (83.3% vs 32.1%, P = 0.005). Resolved CSC eyes with abnormal choriocapillary flow demonstrated more recurrence than eyes with normal choriocapillary flow (42.1% vs 9.5%, P = 0.017). Conclusions and Relevance The pattern of choriocapillary flow abnormalities on OCTA can indicate CSC disease activity. Because eyes with resolved CSC showing abnormal choroidal flow have a high recurrence rate, they should be carefully followed‐up.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 53%

See 1 more Smart Citation

Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy

Seo

Yoon

2019

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…16 However Liu et al in a meta-analysis and review concluded that there was insufficient evidence for the superiority of Bevacizumab over other modalities. 17 In our study, though treatment with Bevacizumab resulted in significant overall improvement, but 4 out of 10 cases failed to resolve fully during this short period of follow up. Bevacizumab therefore may be effective as an adjunct to reduce the subretinal fluid but its role as a primary therapy is debatable.…”

Section: Discussionmentioning

confidence: 91%

Micropulse diode laser versus bevacizumab in chronic central serous chorioretinopathy: a pilot study

Khan

Joshi²,

Gupta

2017

Int J Clin Trials

View full text Add to dashboard Cite

Background: Central serous chorioretinopathy (CSC) is an idiopathic condition with an illdefined aetiopathogenesis and no clearly effective treatment. The choice of treatment include thermal laser photocoagulation, photodynamic therapy (PDT), subthreshold micropulse laser and anti VEGF. Methods: In a prospective nonrandomized pilot trial we evaluated two of these modalities subthreshold micropulse laser treatment and intravitreal anti VEGF in 20 consecutive cases of non-resolving CSC of duration 3 to 6 months with vision below 6/12 treated with either Bevacizumab for leakage close to fovea or subthreshold micropulse 810 diode laser for extrafoveal leakage (10% duty cycle, 100 µ spot size) as seen on fluorescein angiography.Results: At 6 months follow up complete resolution was seen in 9/10 in laser and 6/10 in Avastin group. The mean visual acuity improved from Log MAR 0.61 ± 0.17 at baseline to Log MAR 0.07± 0.11 post treatment in laser group and from Log MAR 0.59 ± 0.17 to Log MAR 0.18 ± 0.09 in the Avastin group . Similarly mean central macular thickness decreased from 607 µ ± 162.1 to 206 µ ± 55 in laser group and from 601 µ ± 182 to 262 µ ± 75 in those receiving Avastin. Both visual outcome and resolution of serous detachment was better with Micropulse laser as compared to Bevacizumab. Conclusions: Micropulse diode laser treatment of CSC has higher rate of resolution and better visual outcome as compared to Bevacizumab injections.

show abstract

“…It is typically a unilateral disorder predominantly affecting males in their 3 rd and 4 th decades of life 2. The pathogenesis of the disease is not clearly understood, but the postulated pathophysiology include stasis, ischemia, and/or inflammation of inner choroid that leads to hyper permeable choroidal vasculature, secondary RPE changes and neurosensory retinal detachment 3,4. Known systemic risk factors associated with CSCR include type A personality, stress, hypertension, smoking, exogenous steroid use, pregnancy, acid peptic disease, Helicobacter pylori infection, obstructive sleep apnea, alcohol use, use of sympathomimetic agents, use ofphosphodiesterase-5 inhibitors (Sildenafil) and collagen vascular disease (SLE, Sarcoidosis) 2,5,6…”

Section: Introductionmentioning

confidence: 99%

Factors affecting the visual outcome in acute central serous chorioretinopathy

Islam¹,

Farooq²,

Mehboob³

2017

Pak J Med Sci

View full text Add to dashboard Cite

Objective:To determine the visual outcome in patients with acute Central serous chorioretinopathy (CSCR) and to analyze the association of clinical, angiographic and tomographic factors with final visual outcome in Pakistani population.Methods:This study was conducted at AFIO Rawalpindi and PNS Shifa Naval hospital Karachi from November 2011 to August 2016. Fifty five eyes of 53 patients with acute CSCR were included. All patients underwent a detailed ophthalmic examination including SD OCT imaging at baseline, One month and three month and FFA was performed at baseline. Primary outcome measures were measurement of initial and final BCVA and CFT. SPSS 13.0 was used for the analysis of data.Results:Mean age of study population was 36.66 ± 6.24 years. On OCT mean CFT at baseline was 467.49 ± 144.80 µm in affected eye, whereas mean CFT measurements at final follow up was 244.67 ± 32.99 µm (p <0.01). Presenting mean log MAR BCVA was 0.47 ± 0.25 and final mean log MAR BCVA was 0.18 ± 0.14 (p <0.01). Baseline BCVA showed statistically significant association with final BCVA (p=0.03).Conclusion:Presenting VA of 6/12 or better is associated with favorable visual outcome in patients with acute CSCR.

show abstract

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients

Cited by 22 publications

References 43 publications

Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy

Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy

Micropulse diode laser versus bevacizumab in chronic central serous chorioretinopathy: a pilot study

Factors affecting the visual outcome in acute central serous chorioretinopathy

Contact Info

Product

Resources

About